Glythera-led consortium wins Industrial Biotechnology Catalyst funding

27th July 2015

Glythera-led consortium wins Industrial Biotechnology Catalyst funding   £248,000 to develop high-throughput glycosylation assay Glythera Limited, the next generation Antibody Drug Conjugate (ADC) company, today announces  that, through a consortium with GlycoSeLect Ltd, specialists in the development and production of recombinant prokaryotic lectins and the Biologics unit of the Centre for Process Innovation (CPI), a UK-based technology innovation centre and part of the High Value Manufacturing Catapult, they have been awarded £248,000 by Innovate UK, the UK…government’s innovation agency, to develop a high-throughput glycosylation assay to facilitate the development of next generation biological therapeutics.

The Early Stage Feasibility Study award will support the development of a novel, rapid and high-throughput Lectin based analytical methodology that will be used to further streamline drug development pathways using Glythera’s PermaCarb™ technology platform.

Glythera has previously demonstrated that direct substitution of naturally occurring glycans with its PermaCarb™ platform has the potential to improve drug bioavailability whilst also correcting potentially immunogenic non-human glycosylation profiles. This approach has broad applications in drug discovery, development and production, especially in the high-value biobetter & biosimilar markets.

The project aims to demonstrate the feasibility of using novel, selective recombinant prokaryotic lectins (RPLs) to develop a companion assay to monitor and characterise specific biotherapeutic glycosylation profiles in a high throughput, low cost manner. GlycoSeLect has previously developed a series of glycan selective RPLs and demonstrated applicability for the characterisation, purification and manufacturing of biotherapeutics. Transition to a rapid analytical methodology will add further intensification to Glythera’s existing manufacturing processes, allowing rapid characterisation of drug intermediates as well as the final product.

For more information go to glythera.com/news-events/press-release